stoxline Quote Chart Rank Option Currency Glossary
  
Genelux Corporation (GNLX)
2.28  0.04 (1.79%)    11-19 16:00
Open: 2.22
High: 2.32
Volume: 210,007
  
Pre. Close: 2.24
Low: 2.11
Market Cap: 110(M)
Technical analysis
2026-11-19 4:35:23 PM
Short term     
Mid term     
Targets 6-month :  3.05 1-year :  3.56
Resists First :  2.61 Second :  3.05
Pivot price 1.98
Supports First :  2.09 Second :  1.76
MAs MA(5) :  2.06 MA(20) :  2
MA(100) :  2.53 MA(250) :  2.87
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  76.3 D(3) :  54.4
RSI RSI(14): 57.1
52-week High :  5.88 Low :  1.76
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GNLX ] has closed Bollinger Bands are 29.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.32 - 2.33 2.33 - 2.34
Low: 2.09 - 2.1 2.1 - 2.11
Close: 2.26 - 2.28 2.28 - 2.29
Company Description

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.

Headline News

Tue, 17 Nov 2026
Genelux (NASDAQ:GNLX) Widens Quarterly Loss as Research Spending Climbs - kalkine.ca

Tue, 17 Nov 2026
Genelux Corporation (GNLX) Tops Q3 EPS by 2c - StreetInsider

Mon, 16 Nov 2026
Genelux Q3 Results: Loss widens 9.5% YoY to $(0.23), misses estimates - scanx.trade

Mon, 16 Nov 2026
Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates - GlobeNewswire

Mon, 16 Nov 2026
Going-concern doubt accompanies $5.1M in net share-sale proceeds at Genelux (GNLX). - Stock Titan

Mon, 16 Nov 2026
Genelux Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 - www.marketscreener.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 45 (M)
Held by Insiders 3.653e+007 (%)
Held by Institutions 12.1 (%)
Shares Short 4,100 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.628e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -455 %
Return on Assets (ttm) 275 %
Return on Equity (ttm) -77.9 %
Qtrly Rev. Growth 8000 %
Gross Profit (p.s.) 0
Sales Per Share -269.6
EBITDA (p.s.) 12121.2
Qtrly Earnings Growth -0.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -25 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 4.17
Stock Dividends
Dividend 0
Forward Dividend 4.64e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android